Immunotherapy combo shrinks liver tumors before ablation in early trial
NCT ID NCT03753659
First seen Mar 29, 2026 · Last updated May 01, 2026 · Updated 3 times
Summary
This trial tested whether giving the immunotherapy drug pembrolizumab before and after local ablation (using heat or radiation to destroy tumors) could improve outcomes for 30 people with early-stage liver cancer. The goal was to see if the drug could shrink tumors enough to make ablation more effective. While the approach aims to control the disease, it is not a cure because liver cancer can return and ongoing monitoring is needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hannover Medical School
Hanover, Lower Saxony, 30625, Germany
Conditions
Explore the condition pages connected to this study.